Select Publications

Bushey RT, Moody MA, Nicely NL, Haynes BF, Munir Alam SM, Keir ST, Bentley RC, Choudhury KR, Gottlin EB, Campa MJ, Liao H-X and Edward F. Patz, Jr. A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. Cell Reports 2016: 15(7):1505-13.

Campa MJ, Moody MA, Zhang R, Liao HX, Gottlin EB, Patz EF Jr. Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery. Cancer Immunol Immunother. 2016: 65(2) 3226-31.

Campa MJ, Gottlin EB, Bushey RT, Patz EF Jr. Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy. Cancer Immunol Res 2015: 3(12):1325-32.

Patz EF Jr, Campa MJ, Gottlin EB, Trotter PR, Herndon JE 2nd, Kafader D, Grant RP, Eisenberg M. Biomarkers to help guide management of patients with pulmonary nodules. Am J Respir Crit Care Med. 2013: 188(4):461-5.

Roberts AS, Campa MJ, Gottlin EB, Jiang C, Owzar K, Kindler HL, Venook AP, Goldberg RM, O’Reilly EM, Patz EF Jr. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer 2012: 118(2):571-8.

Gottlin, EB, Bentley RC, Campa MJ, Pisetsky DS, Herndon II, James E, Patz Jr EF., The Association of Intratumoral Germinal Centers with Early Stage Non-Small Cell Lung Cancer. J Thorac Oncol. 2011 Oct; 6(10):1687-90.

Amornsiripanitch N, Hong S, Campa MJ, Frank MM, Gottlin EB, Patz Jr EF.  Complement factor H autoantibodies are associated with early stage NSCLC. Clinical Cancer Research 2010: 16(12) 3226-3231.

DeArmond PD, West GM, Anbalagan V, Campa MJ, Patz EF Jr, Fitzgerald MC.  Discovery of novel cyclophilin A ligands using an H/D exchange-and Mass spectrometry-based strategy. J Biomol Screen. 2010 Oct; 15(9):1051-62.

Gottlin EB, Guan XR, Pegram C, Cannedy A,Campa MJ, Patz Jr EF.  Isolation of novel EGFR-specific VHH domains. J Biomolecular Screening 2009; 14:77-85.

Hopper ED, Pittman AMC, Tucker CL, Campa MJ, Patz Jr EF, Fitzgerald MC. Hydrogen/deuterium exchange- and protease digestion-based screening assay for protein-ligand binding detection. Anal Chem 2009; 81(16):6860-6867.

Hopper ED, Roulhac PL, Campa MJ, Patz Jr EF, Fitzgerald MC.  Throughput and efficiency of a MASS spectrometry-based high throughput screening assay for protein-ligand binding detection. J Am Soc Mass Spectrom. 2008;19(9):1303-11.

Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, GuanX R, Herndon JE II. A panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 2007; Dec10.25:5578-5583.

Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi M, Harpole DH, Patz EF. Tumor infiltrating FOXP3+Regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;107: 2866-2972.

Howard BA, Furmai R, Campa MJ, Rabbani ZN, VujaskovicZ, Wang X, Patz Jr EF. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small cell lung tumor growth in vivo. Cancer Res 2005;65: (19)8853-8860.

Howard BA, Zheng Z, Campa MJ, Wang MZ, Sharma A, Haura E, Herndon JE, Fitzgerald MC, Bepler G, Patz EF. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer 2004;46:313-323.

Campa MJ, Wang MZ, Howard, B, Fitzgerald MC, Patz Jr EF. Protein Expression Profiling Identifies Macrophage Migration Inhibitory Factor and Cyclophilin A as Potential Molecular Targets Non-Small Cell Lung Cancer. Cancer Res 2003; 63:1652-1656.

Additional publications from the Patz lab can be found by clicking this link.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.